{"entity":{"id":"2031","kind":"year","name":"2031 in oncology","aka":["2031"],"tldr":"Everything OnCo dates to 2031: 7 entries, 7 expected dates. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"7 dated entries in OnCo fall in 2031: 7 expected dates.\n\nOf those, 5 to the day and 2 to the month. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2030","2032"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2031,"events":[{"group":"expected","date":"2031-01","precision":"month","title":"NHS-Galleri: primary-endpoint paper (stage III/IV incidence) not yet on Europe PMC; registry study completion, with cancer-specific mortality follow-up, listed...","note":"Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.","from":"ctdna-tests","refs":["nhs-galleri","galleri","stage-shift"]},{"group":"expected","date":"2031-01-01","precision":"day","title":"IMCODE003 primary completion: adjuvant autogene cevumeran plus atezolizumab and modified FOLFIRINOX versus modified FOLFIRINOX alone after resection (260 estima...","note":"Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...","from":"pancreatic-roadmap","refs":["nct05968326","autogene-cevumeran","neoantigen-mrna-vaccine","paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025"]},{"group":"expected","date":"2031-02-28","precision":"day","title":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases...","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"nct07271355","refs":[]},{"group":"expected","date":"2031-05-30","precision":"day","title":"Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progress...","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"nct07711002","refs":[]},{"group":"expected","date":"2031-07-31","precision":"day","title":"Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma: primary completion","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"nct05864534","refs":[]},{"group":"expected","date":"2031-10","precision":"month","title":"Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV I...","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"nsclc-2","refs":[]},{"group":"expected","date":"2031-12-30","precision":"day","title":"Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based C...","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"nct07680790","refs":[]}]},"route":"/years/2031/","neighbours":{"year":[{"id":"2030","kind":"year","name":"2030 in oncology","route":"/years/2030/"},{"id":"2032","kind":"year","name":"2032 in oncology","route":"/years/2032/"}]}}